July 2, 2026
For a decade, cannabis retail ran on strain names. That's the thing changing in 2026. A growing share of shoppers now pick products by cannabinoid blend instead, and the so-called minor cannabinoids, CBN, CBG, and THCV, are the reason several industry outlooks are calling this their breakout year (Rolling Stone Culture Council).
If you sell into dispensaries, a category shift like this is a stocking event. New SKUs, new brands, new shelf logic, and new budget. Here's what's coming and why it matters for outreach.
They're the compounds beyond the familiar THC and CBD. Brands position each around a specific use: CBN around sleep, CBG around focus and recovery, THCV around appetite and energy (Kolas). Those are marketing positions tied to how products are formulated and sold, not settled medical claims, and operators should treat them that way in their own copy.
The point for retail is that they let a brand sell an outcome (a sleep gummy, a daytime focus drop) rather than a strain. That reframes the whole shelf.
The momentum is in the numbers. By one industry analysis, CBN edibles climbed from about 4% of the edibles category in 2020 to roughly 25% by 2025, an increase of more than 500% in share (Waterbeds 'n' Stuff). The broader minor-cannabinoid market was pegged near $11.5 billion in 2023 with forecasts toward $33 billion by 2030, a roughly 15% annual clip (Rolling Stone Culture Council).
Two things make it a 2026 story specifically. Fast-acting formats that take effect in about 15 minutes make precise dosing of these compounds practical, and consumers are increasingly choosing products by cannabinoid blend over strain name (Kolas).
A store moving toward functional, blend-based products has to change how it merchandises. Strain-first menus get reorganized around effects. New cannabinoid lines mean new vendor relationships, new packaging, new menu and POS categories, and staff training on what CBG even is.
That's the opening. Every category shift forces a wave of operational spending, and the dispensaries leaning in are the ones rebuilding their assortment right now.
A dispensary stocking CBN, CBG, and THCV lines is telling you it's an early adopter chasing the wellness-minded buyer. That profile tends to be more receptive to new vendors than a store standing pat on flower and familiar SKUs.
The practical move is to spot which operators are expanding their assortment and reach them while they're actively choosing partners. A current, license-verified list with owner-level contacts is how you get to those buyers before the shelf is already full.
What are minor cannabinoids? Compounds other than THC and CBD, such as CBN, CBG, and THCV, sold for targeted effects. Brands position CBN around sleep, CBG around focus, and THCV around appetite (Kolas).
Why are they trending in 2026? Fast-acting formats make precise dosing practical, and shoppers are increasingly buying by cannabinoid blend instead of strain. CBN edibles alone grew from about 4% to 25% of the edibles category between 2020 and 2025 (Waterbeds 'n' Stuff).
Why does it matter for B2B sellers? A new category forces dispensaries to restock, re-merchandise, and find new suppliers, which opens budget and partner decisions.
The stores rebuilding their shelves around new categories are the ones worth reaching first. See verified, owner-level dispensary contacts across six states. Free preview here.
Holden Leads
Holden Leads tracks every licensed dispensary across California, Michigan, Illinois, and Massachusetts — cross-referenced weekly against official state regulatory databases and enriched with phone numbers, emails, websites, and social profiles. Stop manually hunting for contact info. Get the full list today.